Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CanSino Biologics, Inc. Class H ( (HK:6185) ) just unveiled an update.
CanSino Biologics Inc. reported its unaudited financial results for the first quarter of 2025, showing a 20.02% increase in operating revenue compared to the same period last year. Despite the revenue growth, the company experienced a net loss attributable to shareholders, although significantly reduced from the previous year’s loss, indicating a potential improvement in financial health. The report highlights the company’s ongoing challenges in achieving profitability, yet suggests a positive trend in revenue generation.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a biotechnology company based in China, focusing on the development and production of innovative vaccines for infectious diseases. The company operates within the pharmaceutical industry and is listed on the Hong Kong Stock Exchange.
YTD Price Performance: -3.02%
Average Trading Volume: 1,674,837
Technical Sentiment Signal: Sell
Current Market Cap: HK$9.37B
For an in-depth examination of 6185 stock, go to TipRanks’ Stock Analysis page.